DISRUPT CAD III

By The Numbers

392
Patients
50
Global Sites
2
Year Follow-Up
30
Day MACE Rate = Primary Safety Endpoint
<50%
Residual Stenosis = Primary Effectiveness Endpoint
~100
Patient OCT Sub-Study

DISRUPT CAD III Study Leadership

dean j kereiakes md
Dean J. Kereiakes, M.D., FACC, FSCAI
Co-Principal Investigator
Medical Director, The Christ Hospital Heart and Vascular Center
Cincinnati, OH
jonathan hill
Jonathan Hill, M.D.
Co-Principal Investigator
Consultant Cardiologist King’s College Hospital
London, UK
gregg w stone
Gregg W. Stone, M.D., FACC, FSCAI
Study Chairman
Professor of Medicine, Columbia University Medical Center
New York City, NY

Countries Included in DISRUPT CAD III

World Map
United States
a
United Kingdom
a
France
a
Germany
a

Ready to Make Waves with Shockwave IVL?

ico email Connect